Effect of tumor necrosis factor–alfa inhibitor and methotrexate therapy on total cholesterol, high-density lipoprotein, and low-density lipoprotein in psoriasis/psoriatic arthritis and rheumatoid arthritis patients

2013 ◽  
Vol 68 (4) ◽  
pp. AB199
Keyword(s):  
Rheumatoid Arthritis ◽  
Psoriatic Arthritis ◽  
Tumor Necrosis Factor ◽  
High Density Lipoprotein ◽  
Tumor Necrosis ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Methotrexate Therapy ◽  
Low Density ◽  
Necrosis Factor

Tumor Necrosis Factor-α Inhibitor Use Is Not Associated with Lipid Changes in Rheumatoid Arthritis

2012 ◽  
Vol 39 (5) ◽  
pp. 946-948 ◽  
Author(s):  
ANDRONIKI BILI ◽  
STEPHANIE J. MORRIS ◽  
JENNIFER A. SARTORIUS ◽  
H. LES KIRCHNER ◽  
JANA L. ANTOHE ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipid Levels ◽  
Tnf Α ◽  
Factor Α ◽  
Necrosis Factor

Objective.To determine the association of use of tumor necrosis factor-α (TNF-α) inhibitors with differences in lipid levels in patients with rheumatoid arthritis (RA).Methods.We studied 807 patients with incident RA to compare differences in lipid levels in TNF-α inhibitor users versus nonusers, with adjustment for relevant covariables.Results.TNF-α inhibitor use was not associated with differences in levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC), triglycerides, LDL:HDL, or TC:HDL compared to nonusers.Conclusion.Use of TNF-α inhibitor was not associated with differences in lipid levels in patients with RA.

High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study

2013 ◽  
Vol 40 (6) ◽  
pp. 825-830 ◽  
Author(s):  
Anna Jamnitski ◽  
Johannes H. Levels ◽  
Inge A. van den Oever ◽  
Michael T. Nurmohamed
Keyword(s):  
Rheumatoid Arthritis ◽  
Tumor Necrosis Factor ◽  
High Density Lipoprotein ◽  
Tumor Necrosis ◽  
Density Lipoprotein ◽  
High Density ◽  
Tnf Inhibitors ◽  
Eular Response ◽  
Amyloid A ◽  
Necrosis Factor

Objective.We investigated changes in high-density lipoprotein (HDL) profiling in patients with rheumatoid arthritis who started treatment by taking tumor necrosis factor (TNF) inhibitors. The patients were stratified for European League Against Rheumatism (EULAR) response.Methods.A group of 100 patients naive for TNF inhibitors at baseline were randomly selected from 204 adalimumab-treated and 203 etanercept-treated patients on the basis of their EULAR response. HDL profiling was measured using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.Results.In EULAR good responders, mass charged markers representing serum amyloid A (SAA-1 and -2) decreased significantly after 4 months’ therapy. There were no significant differences in HDL profiling in EULAR nonresponders.Conclusion.Effective suppression of inflammation with TNF inhibitors results in favorable changes in HDL composition.

Sign in / Sign up

Export Citation Format

Share Document